Mimedx (MDXG) Revenue (2011 - 2026)
Mimedx recorded quarterly Revenue of $59.0 million in Q1 2026, down 50.05% quarter-over-quarter from $118.1 million in Q4 2025, and down 33.12% year-over-year from $88.2 million in Q1 2025.
Mimedx's Revenue history runs 16 years deep, the most recent figure standing at $59.0 million for Q1 2026.
- In Q1 2026, Revenue fell 33.12% year-over-year to $59.0 million; the TTM figure through Mar 2026 stood at $389.4 million (up 10.51% YoY), while the FY2025 annual figure was $418.6 million, up 19.99% from the prior year.
- Revenue came in at $59.0 million for Q1 2026 at Mimedx, down from $118.1 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $118.1 million in Q4 2025 to a low of $58.9 million in Q1 2022.
- A 5-year average of $83.3 million and a median of $84.1 million in 2024 frame the typical range for Revenue.
- Across the five-year window, Revenue jumped 46.37% in 2022 and plunged 33.12% in 2026, its largest moves.
- Mimedx's Revenue stood at $74.4 million in 2022, then gained by 16.75% to $86.8 million in 2023, then advanced by 7.0% to $92.9 million in 2024, then climbed by 27.11% to $118.1 million in 2025, then tumbled by 50.05% to $59.0 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $59.0 million, $118.1 million, and $113.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | 58.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.99 Mn |
| Dec 31, 2025 | 118.10 Mn |
| Sep 30, 2025 | 113.73 Mn |
| Jun 30, 2025 | 98.61 Mn |
| Mar 31, 2025 | 88.21 Mn |
| Dec 31, 2024 | 92.91 Mn |
| Sep 30, 2024 | 84.06 Mn |
| Jun 30, 2024 | 87.21 Mn |
| Mar 31, 2024 | 84.71 Mn |
| Dec 31, 2023 | 86.83 Mn |
| Sep 30, 2023 | 81.71 Mn |
| Jun 30, 2023 | 81.26 Mn |
| Mar 31, 2023 | 71.68 Mn |
| Dec 31, 2022 | 74.38 Mn |
| Sep 30, 2022 | 67.69 Mn |
| Jun 30, 2022 | 66.88 Mn |
| Mar 31, 2022 | 58.89 Mn |
| Dec 31, 2021 | 50.81 Mn |
| Sep 30, 2021 | 63.07 Mn |
| Jun 30, 2021 | 68.17 Mn |
| Mar 31, 2021 | 59.97 Mn |
| Dec 31, 2020 | 68.55 Mn |
| Sep 30, 2020 | 64.30 Mn |
| Jun 30, 2020 | 53.65 Mn |
| Mar 31, 2020 | 61.74 Mn |
| Dec 31, 2019 | 76.40 Mn |
| Sep 30, 2019 | 88.86 Mn |
| Jun 30, 2019 | 67.44 Mn |
| Mar 31, 2019 | 66.56 Mn |
| Dec 31, 2018 | 92.59 Mn |
| Sep 30, 2018 | 86.96 Mn |
| Jun 30, 2018 | 95.42 Mn |
| Mar 31, 2018 | 84.15 Mn |
| Dec 31, 2017 | 87.86 Mn |
| Sep 30, 2017 | 84.00 Mn |
| Jun 30, 2017 | 80.49 Mn |
| Mar 31, 2017 | 68.80 Mn |
| Dec 31, 2016 | 69.88 Mn |
| Sep 30, 2016 | 64.43 Mn |
| Jun 30, 2016 | 57.34 Mn |
| Mar 31, 2016 | 53.37 Mn |
| Dec 31, 2015 | 51.84 Mn |
| Sep 30, 2015 | 49.02 Mn |
| Jun 30, 2015 | 45.68 Mn |
| Mar 31, 2015 | 40.77 Mn |
| Dec 31, 2014 | 39.57 Mn |
| Sep 30, 2014 | 33.52 Mn |
| Jun 30, 2014 | 25.57 Mn |
| Mar 31, 2014 | 19.56 Mn |
| Dec 31, 2013 | 17.99 Mn |
| Sep 30, 2013 | 16.12 Mn |
| Jun 30, 2013 | 13.52 Mn |
| Mar 31, 2013 | 11.56 Mn |
| Dec 31, 2012 | 10.51 Mn |
| Sep 30, 2012 | 7.95 Mn |
| Jun 30, 2012 | 4.88 Mn |
| Mar 31, 2012 | 3.71 Mn |
| Dec 31, 2011 | 2.64 Mn |
| Sep 30, 2011 | 2.15 Mn |
| Jun 30, 2011 | 1.93 Mn |
| Mar 31, 2011 | 1.04 Mn |